|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on August 15, 2002; DOI 10.1182/blood-2002-03-0755.
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Division of Hematology-Oncology, Weill Medical
College of Cornell University, New York, NY; and Molecular/Cancer
Biology Laboratory and Ludwig Institute for Cancer Research, Haartman
Institute and Helsinki University Hospital, Biomedicum Helsinki,
University of Helsinki, Finland.
Human CD133 (AC133)+CD34+ stem and
progenitor cells derived from fetal liver and from bone marrow and
blood incorporate a functional population of circulating
endothelial precursor cells. Vascular endothelial growth factor
receptor 3 (VEGFR-3) regulates cardiovascular development and
physiological and pathological lymphangiogenesis and angiogenesis.
However, the origin of VEGFR-3+ endothelial cells (ECs) and
the mechanisms by which these cells contribute to postnatal
physiological processes are not known, and the possible existence of
VEGFR-3+ lymphatic or vascular EC progenitors has not been
studied. Using monoclonal antibodies to the extracellular domain of
VEGFR-3, we show that 11% ± 1% of CD34+ cells isolated
from human fetal liver, 1.9% ± 0.8% CD34+ cells from
human cord blood, and 0.2% ± 0.1% of CD34+ cells from
healthy adult blood donors are positive for VEGFR-3. CD34+VEGFR-3+ cells from fetal liver coexpress
the stem/precursor cell marker CD133 (AC133). Because mature ECs do not
express CD133, coexpression of VEGFR-3 and CD133 on CD34+
cells identifies a unique population of stem and progenitor cells. Incubation of isolated CD34+VEGFR-3+ cells in
EC growth medium resulted in a strong proliferation (40-fold in 2 weeks) of nonadherent VEGFR-3+ cells. Plating of these
cells resulted in the formation of adherent VEGFR-3+Ac-LDL+ (Ac-LDL = acetylated
low-density lipoprotein) EC monolayers expressing various vascular and
lymphatic endothelial-specific surface markers, including CD34,
VE-cadherin, CD51/61, CD105, LYVE-1, and podoplanin. These data
demonstrate that human CD34+CD133+ cells
expressing VEGFR-3 constitute a phenotypically and functionally distinct population of endothelial stem and precursor cells that may
play a role in postnatal lymphangiogenesis and/or angiogenesis.
(Blood. 2003;101:168-172) Members of the vascular endothelial growth
factor (VEGF) family, including VEGF, VEGF-B, VEGF-C, and VEGF-D,
regulate various aspects of blood vascular and lymphatic growth and
function. VEGF acts through the tyrosine kinase receptors VEGFR-2 (KDR,
Flk-1) and VEGFR-1 (Flt-1), which convey signals that are
essential for embryonic angiogenesis and hematopoiesis.1
VEGF-C and VEGF-D, in turn, bind to and mediate signals to the blood
vascular and lymphatic endothelium through VEGFR-2 and VEGFR-3.
The resulting signals regulate cardiovascular development,
angiogenesis, and lymphangiogenesis.2,3 VEGF-C,
which is expressed by various human cancers,4-6 has a
potent angiogenic effect in vivo7 and also induces
lymphangiogenesis, which in tumors can promote the dissemination of
tumor cells to regional lymph nodes.8-14
The expression of the VEGFR-3 gene starts during mouse embryonic
day 8.5 in developing blood vessels, and VEGFR-3-deficient embryos die
at midgestation owing to defects in the remodeling of primary vascular
networks.15 In adult tissues, VEGFR-3 expression occurs
mainly in the lymphatic endothelia.15-18 In healing
wounds, VEGFR-3-positive lymphatic vessels appear in the wound
concurrently with blood vessels but regress quickly.19
However, VEGFR-3-expressing endothelial cells (ECs) can also be found
in fenestrated capillaries of several adult organs, including bone
marrow, splenic and hepatic sinusoids, kidney glomeruli, and endocrine
glands.18 Notably, in human cancer VEGFR-3-expressing
vascular ECs are detected in angiogenic capillaries,5,20
and in nude mice inactivation of VEGFR-3 signaling by blocking
antibodies suppresses tumor growth by inhibiting the
angiogenesis.21
Recent evience suggests that in adult humans circulating
endothelial precursor (CEP) cells may be recruited from the stem-cell reservoirs to the peripheral circulation, and that they play a role in
postnatal angiogenesis associated with vascular trauma or tumor
growth.22-31 Recent data also demonstrate that
lymphangiogenesis, facilitated by VEGFR-3 signaling, contributes to
cancer dissemination.9,10,12,13,32,33 However, the origin
of lymphatic ECs (LECs) is not known. It is conceivable that a
lymphangiogenic switch promotes the recruitment of LECs from
neighboring pre-existing lymphatic vessels or recruits LEC precursors
from the bone marrow. However, the possible existence of LEC
progenitors has not been studied. Here we demonstrate that a subset of
CD34+ cells coexpress VEGFR-3 and CD133. These cells are
functionally a unique population of progenitor cells with the capacity
to differentiate into lymphatic or vascular ECs. They could contribute
to postnatal lympangiogenesis and/or angiogenesis.
Positive selection of human CD34+ cells by magnetic
cell sorting
Circulating CD34+ cells were also obtained from
peripheral blood samples from growth factor-treated patients and from
healthy blood donors. In brief, mononuclear cell fraction was separated with Ficoll-Hypaque (Amersham Pharmacia, Uppsala, Sweden)
centrifugation and CD34 purification was done with a Clinimacs
CD34-separation kit (Miltenyi Biotech). The purity of
CD34-selected cells was determined by flow cytometry using FITC-labeled
anti-CD34 mAbs (Pharmingen, San Diego, CA). Approval was provided by
the institutional review boards of Weill Medical College of Cornell
University and Helsinki University Central Hospital for these studies.
Informed consent was provided according to the Declaration of Helsinki.
Flow cytometry
Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis
of VEGFR-3 mRNA expression in isolated CD34+ and
CD34  cells by guanidine
isothiocyanate lysis and silica gel membrane purification (RNeasy RNA
extraction kit, Qiagen, Hilden, Germany) according to the
manufacturer's protocol and was quantitated spectrophotometrically. Primers specific for exons 7 and 8 of the human VEGFR-3 gene were used
(the design of the primers was based on published
sequences,35,36 GenBank accession number X68203; sense,
5'-catccagctgttgcccagg-3', and antisense, 5'-gagccactcgacgctgatgaa-3').
For RT-PCR analysis, 1.0 µg of total RNA from each sample was
amplified with an intron-spanning primer pair for the human GAPDH
gene37 and another 1.0 µg was amplified with the VEGFR-3
primer pair. The OneStep RT-PCR kit (Qiagen) was used. After a
30-minute reverse transcription reaction at 54°C and an initial
denaturation at 95°C for 15 minutes, a 40-cycle PCR reaction was
carried out, using the following amplification profile: denaturation at
94°C for 45 seconds, annealing at 65°C for 45 seconds,
extension at 72°C for 45 seconds. For the GAPDH primers, a 35-cycle
amplification was performed with annealing at 63°C. The PCR products
were then electrophoresed on 1.5% agarose gel, stained with 0.5 µg/mL ethidium bromide, visualized under ultraviolet (UV)
light, and photographed.
Liquid cultures of human CD34+ cells Freshly isolated CD34+ cells from human FL were analyzed for the presence of CD133+VEGFR-3+ cells. Subsequently, 105 CD34+ cells were cultured in EC medium containing medium 199 (M199; GIBCO-BRL, Gaithersburg, MD) supplemented with 18% fetal bovine serum (HyClone, Logan, UT), 2% human serum, VEGF at 1 ng/mL (R&D Systems, Minneapolis, MN), bFGF at 2.5 ng/mL (Sigma, St Louis, MO), heparin at 5 U/mL, and VEGF-C at 60 ng/mL. The recombinant human VEGF-C was produced and purified as described earlier.38-40 As a control, the same experiments were performed in parallel with the freshly isolated CD34
cells from human FL. The number of viable nonadherent cells in the
cultures was determined at 3, 5, 7, and 14 days by means of a
bright-line counting chamber. The incubation resulted in a strong proliferation of the CD34-selected nonadherent cells. To prepare the
cells for flow cytometry, the nonadherent cells were collected, washed
with phosphate-buffered saline (PBS), and stained with PE- or
FITC-labeled mAbs.
Generation of EC monolayers from human CD34+ cells in vitro Freshly isolated CD34+ cells from FL were analyzed for the presence of CD133+VEGFR-3+ cells. Subsequently, the cells were cultured in EC medium. After 3 days, nonadherent cells were transferred to plastic dishes and grown in the same medium for 2 to 4 weeks. This incubation resulted in attachment and proliferation of the CD34-selected cells into monolayers of mature ECs. After removal of the nonadherent cells, the adherent cell population was studied by 2-color flow cytometry. In addition, the ECs were quantified by means of low-density lipoprotein (LDL) incorporation. Dil-conjugated acetylated LDL (1 µg/mL; Intracel, Rockville, MD) was added to the media for 4 hours, and EC-specific labeling was assessed by flow cytometry.Immunostaining of ECs To further characterize EC monolayers generated from FL CD34+ cells in vitro, cells cultured in the chamber slides were fixed for 2 minutes in acetone and subjected to double immunostaining analyses using mouse monoclonal antibodies against human VEGFR-3 (clone 9d9) and rabbit antisera against human LYVE-141 (kindly provided by David G. Jackson, Oxford, and by Pirjo Laakkonen and Erkki Ruoslahti, La Jolla, CA) or affinity-purified rabbit antihuman podoplanin.42 The double staining procedure was essentially as described earlier.43 The slides were first rehydrated and incubated for 30 minutes in 4% normal goat serum at room temperature. The slides were incubated for 1 hour at room temperature with the rabbit polyclonal anti-LYVE-1 antiserum at a dilution of 1:100 or with the rabbit polyclonal antipodoplanin at a dilution of 1:300. A subsequent incubation for 30 minutes in biotinylated antirabbit serum was followed by a 30-minute incubation using reagents of the Vectastain Elite ABC Peroxidase antirabbit IgG kit (Vector Laboratories, Burlingame, CA). Peroxidase activity was developed with NovaRED substrate (Vector Laboratories) for 10 minutes. Subsequently, the slides were rehydrated and incubated for 30 minutes in 4% in normal horse serum at room temperature. The slides were then incubated for 1 hour with mouse monoclonal anti-VEGFR-3 antibodies at a concentration of 2.0 µg/mL. A subsequent incubation for 30 minutes in biotinylated antimouse serum was followed by a 30-minute incubation using reagents of the Vectastain ABC Alkaline phosphatase antimouse IgG kit (Vector Laboratories). Alkaline phosphatase activity was developed with Vector Blue alkaline phosphate substrate (Vector Laboratories) for 20 minutes. Negative controls were performed by omitting one or both of the primary antibodies or by using irrelevant primary antibodies.Preparation of human umbilical vein EC (HUVEC) monolayers HUVECs were isolated from freshly obtained umbilical cords by collagenase treatment44 and grown in EC medium. Confluent monolayers from passages 2 to 4 were studied by flow cytometry.Statistical analysis Data are expressed as mean ± standard error (SE) of at least 3 independent experiments.
Identification of a population of circulating CD34+VEGFR-3+ cells VEGFR-3 cell-surface expression was analyzed by 2-color flow cytometry on MACS-selected CD34+ and CD34
cells isolated from human FL. The purity of the CD34+ cells
was routinely 85% to 95%. Using PE-labeled mAbs against the
extracellular domain of VEGFR-3, we found that 11% ± 1% (n = 6)
of CD34+ cells from FL were VEGFR-3+ (Figure
1). No VEGFR-3+ cells could
be detected in the CD34 cell fractions (Figure 1). This
indicates that VEGFR-3+ cells are a small subpopulation of
CD34+ cells.
VEGFR-3 cell-surface expression was also studied on purified CB CD34+ cells (n = 3), on purified peripheral blood CD34+ cells from adult patients treated with cyclophosphamide and granulocyte colony-stimulating factor (G-CSF; n = 16), and on CD34+ cells from healthy adult blood donors (n = 6). VEGFR-3 cell-surface expression was detected in 1.9% ± 0.8% of CD34+ cells from CB. Similarly, the number of VEGFR-3+ cells was generally found to be lower in adult patients (0.8% ± 0.2% of CD34+ cells) and in healthy adult blood donors (0.2% ± 0.1% of CD34+ cells) than in the FL samples. VEGFR-3 mRNA is expressed in CD34+ cells but not in
CD34
cells were negative for VEGFR-3 mRNA. These data are consistent with
the detection of VEGFR-3 cell-surface expression on FL
CD34+ and CD34 cells.
Phenotypic characterization of CD34+VEGFR-3+ cells identifies a population of putative endothelial progenitor cells Coexpression of VEGFR-3 and defined stem/progenitor cell and EC markers on CD34+ cells isolated from FL or CB was analyzed by 2-color flow cytometry. The CD34+VEGFR-3+ cells could represent a heterogeneous population of mature and immature ECs, since CD34 is expressed on both mature and immature ECs. Therefore, CD34+ cells were first analyzed by using PE-conjugated mAbs against the stem-cell marker CD133 (AC133) and Cy2-conjugated anti-VEGFR-3 mAbs. We found that almost all CD34+VEGFR-3+ cells were positive for CD133 (Figure 3). Because mature ECs do not express CD133, coexpression of VEGFR-3 and CD133 on CD34+ cells identifies a unique population of stem and progenitor cells. We also found that about half of the CD34+VEGFR3+ cells also express VE-cadherin or VEGFR-2, markers that have already previously been found on circulating endothelial precursors (Figure 5).27,28,31,45 Only inconsistent, low-level, or nonexistent cell-surface expression of the endothelial-specific markers integrin v 3 heterodimeric complex
(CD51/CD61), endoglin (CD105), and VEGFR-1 could be observed on
isolated CD34+ cells coexpressing VEGFR-3 (Figure 5).
Similarly, no significant cell-surface expression of CD11b or CD14
could be detected on the CD34+VEGFR-3+ cells
(Figure 5).
Expansion of VEGFR-3+ cells in liquid culture Incubation of 105 freshly isolated CD34+ cells from human FL for 2 weeks in EC growth medium containing VEGF, VEGF-C, and bFGF resulted in a strong proliferation (more than 30-fold) of nonadherent cells (Figure 4). Flow cytometry indicated that during the 2-week culture the mean number of nonadherent VEGFR-3+ cells had expanded more than 40-fold (from 11 × 103 to 47 × 104 cells, 11% ± 2% and 14% ± 4% of the total nonadherent cells, respectively; Figure 4).
Generation of ECs from CD34+ cells is associated with expression of VEGFR-3 on the cell surface Incubation of freshly isolated, nonadherent CD34+ cells for 3 to 5 weeks in EC medium resulted in their differentiation into adherent monolayers of ECs. Flow cytometry using PE-labeled anti-VEGFR-3 mAbs indicated that 10% ± 2% of the cells in the monolayers expressed VEGFR-3. All adherent VEGFR-3+ cells incorporated Ac-LDL, confirming that they were ECs (Figure 5). Adherent VEGFR-3+ cells coexpressing CD34, VE-cadherin, CD51/61, or CD105 were also detected (Figure 5). The monolayer cells did not express CD133, thus supporting the notion that CD133+CD34+VEGFR-3+ cells may be considered nonadherent EC precursors with progenitor potential. In double immunostainings, adherent ECs were found to coexpress VEGFR-3+ and lymphatic EC markers LYVE-1 or podoplanin (Figure 6). In cultured confluent HUVECs of passages 2 to 4 we found cell-surface expression of VEGFR-3 on 49% ± 6% of the cells. The surface-marker expression pattern of VEGFR-3+ HUVEC colonies, when analyzed by flow cytometry (CD133-VEGFR-3+CD34+VE-cadherin+CD51/61+CD105+), was similar to that of VEGFR-3+ EC colonies found in the monolayers generated from FL CD34+ cells (Figure 5).
Bone marrow is a rich reservoir of organ-specific pluripotent and committed stem cells. Hematopoietic, endothelial, and mesenchymal stem cells have been shown to reside in the bone marrow, with the potential to be recruited to the peripheral circulation. They have also been shown to contribute to tumor angiogenesis and wound healing. Here, we have demonstrated that CD133+CD34+ cells coexpressing VEGFR-3 are functionally nonadherent EC precursors that have the capacity to differentiate into mature adherent VEGFR-3+ ECs. Both endothelial precursor cells and mature ECs may express similar endothelial-specific markers. In contrast, the expression of CD133 is rapidly down-regulated as progenitors and stem cells differentiate into more mature postmitotic cells.27,46 Mature endothelial cells do not express CD133.27,47 Therefore, CD34+ cells coexpressing VEGFR-3 and CD133 represent a phenotypic and functional subset of stem and progenitor cells. Although the number of circulating CD34+VEGFR-3+ cells was very small in healthy adult blood donors, these cells could be mobilized to the peripheral circulation in pathological conditions, such as tumor growth and wound healing. The adherent
CD133 We also observed CD34+ cell-derived ECs coexpressing VEGFR-3 and the lymphatic EC markers LYVE-141 and podoplanin42 (Figure 6). Interestingly, Makinen et al have recently shown that up to 50% of freshly isolated human ECs (HUVECs and dermal microvascular ECs) were positive for VEGFR-3, and that the number of VEGFR-3+ ECs then decreased upon repeated subculture in vascular EC growth medium.49 The authors concluded that the cultured HUVECs and microvascular ECs consisted of distinct populations of vascular ECs and lymphatic ECs, and that the majority of VEGFR-3+ ECs were of lymphatic endothelial origin. In agreement with these conclusions, when we studied HUVECs of passages 2 to 4, we found cell-surface expression of VEGFR-3 on about half of the cells. These VEGFR-3+ HUVECs had a phenotype comparable to that of VEGFR-3+ ECs in CD34+ cell-derived monolayers. In CD34+ cell-derived monolayers the VEGFR-3+ ECs were more scarce than in HUVEC monolayers, constituting about 10% of the ECs. Taken together, these observations support the concept that a subset of VEGFR-3+ cells on cultured CD34+ cell-derived monolayers are true lymphatic ECs that have differentiated from circulating CD133+CD34+VEGFR-3+ LEC precursors. Mobilization of these LEC precursors might play a role in lymphangiogenesis associated with wound healing or tumor growth. In summary, we have described the developmental potential of human VEGFR-3+ progenitor cells, showing that when cultured in the presence of EC growth factors they give rise to EC monolayers expressing surface markers typical of both vascular and lymphatic ECs. Further identification and characterization of the VEGFR-3+ precursor cell subsets with vascular endothelial potential should define their role in physiological and pathological blood vessel growth. Further studies should also provide a unique approach to prove or disprove the existence of circulating lymphatic EC precursors in adults and their possible role in postnatal lymphatic vessel formation.
Submitted March 11, 2002; accepted August 6, 2002.
Prepublished online as Blood First Edition Paper, August 15, 2002; DOI 10.1182/blood-2002-03-0755.
Supported by grants from the Sigrid Juselius Foundation, the Finnish Medical Foundation, the Maud Kuistila Memorial Foundation, the Academy of Finland; and Helsinki University Hospital Research Fund.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Petri Salven, Division of Hematology-Oncology, Weill Medical College of Cornell University, 1300 York Ave, Room C-606, New York, NY 10021; e-mail: pjs2004{at}med.cornell.edu; petri.salven@helsinki.fl.
1.
Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z.
Vascular endothelial growth factor (VEGF) and its receptors.
FASEB J.
1999;13:9-22
2.
Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K.
Regulation of angiogenesis via vascular endothelial growth factor receptors.
Cancer Res.
2000;60:203-212 3. Karkkainen MJ, Jussila L, Ferrell RE, Finegold DN, Alitalo K. Molecular regulation of lymphangiogenesis and targets for tissue oedema. Trends Mol Med. 2001;7:18-22[CrossRef][Medline] [Order article via Infotrieve].
4.
Salven P, Lymboussaki A, Heikkila P, et al.
Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors.
Am J Pathol.
1998;153:103-108
5.
Valtola R, Salven P, Heikkila P, et al.
VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer.
Am J Pathol.
1999;154:1381-1390 6. Wartiovaara U, Salven P, Mikkola H, et al. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost. 1998;80:171-175[Medline] [Order article via Infotrieve].
7.
Cao Y, Linden P, Farnebo J, et al.
Vascular endothelial growth factor C induces angiogenesis in vivo.
Proc Natl Acad Sci U S A.
1998;95:14389-14394
8.
Jeltsch M, Kaipainen A, Joukov V, et al.
Hyperplasia of lymphatic vessels in VEGF-C transgenic mice.
Science.
1997;276:1423-1425
9.
Karpanen T, Egeblad M, Karkkainen MJ, et al.
Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth.
Cancer Res.
2001;61:1786-1790 10. Mandriota SJ, Jussila L, Jeltsch M, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 2001;20:672-682[CrossRef][Medline] [Order article via Infotrieve]. 11. Veikkola T, Jussila L, Makinen T, et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J. 2001;20:1223-1231[CrossRef][Medline] [Order article via Infotrieve].
12.
Skobe M, Hamberg LM, Hawighorst T, et al.
Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma.
Am J Pathol.
2001;159:893-903 13. Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 2001;7:192-198[CrossRef][Medline] [Order article via Infotrieve].
14.
Stacker SA, Baldwin ME, Achen MG.
The role of tumor lymphangiogenesis in metastatic spread.
FASEB J.
2002;16:922-934
15.
Dumont DJ, Jussila L, Taipale J, et al.
Cardiovascular failure in mouse embryos deficient in VEGF receptor-3.
Science.
1998;282:946-949
16.
Kaipainen A, Korhonen J, Mustonen T, et al.
Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development.
Proc Natl Acad Sci USA.
1995;92:3566-3570
17.
Jussila L, Valtola R, Partanen TA, et al.
Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3.
Cancer Res.
1998;58:1599-1604
18.
Partanen TA, Arola J, Saaristo A, et al.
VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues.
FASEB J.
2000;14:2087-2096
19.
Paavonen K, Puolakkainen P, Jussila L, Jahkola T, Alitalo K.
Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing.
Am J Pathol.
2000;156:1499-1504 20. Partanen TA, Alitalo K, Miettinen M. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer. 1999;86:2406-2412[CrossRef][Medline] [Order article via Infotrieve].
21.
Kubo H, Fujiwara T, Jussila L, et al.
Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis.
Blood.
2000;96:546-553
22.
Asahara T, Murohara T, Sullivan A, et al.
Isolation of putative progenitor endothelial cells for angiogenesis.
Science.
1997;275:964-967
23.
Shi Q, Rafii S, Wu MH, et al.
Evidence for circulating bone marrow-derived endothelial cells.
Blood.
1998;92:362-367 24. Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999;18:3964-3972[CrossRef][Medline] [Order article via Infotrieve]. 25. Murohara T, Ikeda H, Duan J, et al. Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J Clin Invest. 2000;105:1527-1536[Medline] [Order article via Infotrieve]. 26. Rafii S. Circulating endothelial precursors: mystery, reality, and promise. J Clin Invest. 2000;105:17-19[Medline] [Order article via Infotrieve].
27.
Peichev M, Naiyer AJ, Pereira D, et al.
Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors.
Blood.
2000;95:952-958
28.
Gill M, Dias S, Hattori K, et al.
Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells.
Circ Res.
2001;88:167-174
29.
Gehling UM, Ergun S, Schumacher U, et al.
In vitro differentiation of endothelial cells from AC133-positive progenitor cells.
Blood.
2000;95:3106-3112 30. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001;7:1194-1201[CrossRef][Medline] [Order article via Infotrieve]. 31. Reyes M, Dudek A, Jahagirdar B, Koodie L, Marker PH, Verfaillie CM. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest. 2002;109:337-346[CrossRef][Medline] [Order article via Infotrieve].
32.
Beasley NJ, Prevo R, Banerji S, et al.
Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer.
Cancer Res.
2002;62:1315-1320
33.
He Y, Kozaki K, Karpanen T, et al.
Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.
J Natl Cancer Inst.
2002;94:819-825
34.
Batard P, Sansilvestri P, Scheinecker C, et al.
The Tie receptor tyrosine kinase is expressed by human hematopoietic progenitor cells and by a subset of megakaryocytic cells.
Blood.
1996;87:2212-2220
35.
Aprelikova O, Pajusola K, Partanen J, et al.
FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter.
Cancer Res.
1992;52:746-748
36.
Iljin K, Karkkainen MJ, Lawrence EC, et al.
VEGFR3 gene structure, regulatory region, and sequence polymorphisms.
FASEB J.
2001;15:1028-1036 37. Halfter H, Friedrich M, Postert C, Ringelstein EB, Stogbauer F. Activation of Jak-Stat and MAPK2 pathways by oncostatin M leads to growth inhibition of human glioma cells. Mol Cell Biol Res Commun. 1999;1:109-116[CrossRef][Medline] [Order article via Infotrieve]. 38. Joukov V, Sorsa T, Kumar V, et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 1997;16:3898-3911[CrossRef][Medline] [Order article via Infotrieve].
39.
Wise LM, Veikkola T, Mercer AA, et al.
Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1.
Proc Natl Acad Sci U S A.
1999;96:3071-3076 40. Makinen T, Jussila L, Veikkola T, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med. 2001;7:199-205[CrossRef][Medline] [Order article via Infotrieve].
41.
Banerji S, Ni J, Wang SX, et al.
LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan.
J Cell Biol.
1999;144:789-801
42.
Breiteneder-Geleff S, Soleiman A, Kowalski H, et al.
Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium.
Am J Pathol.
1999;154:385-394
43.
Salven P, Anttonen K, Repo H, Joensuu H, Orpana A.
Endotoxins induce and interferon- 44. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J Clin Invest. 1973;52:2745-2756[Medline] [Order article via Infotrieve].
45.
Ogawa M, Kizumoto M, Nishikawa S, Fujimoto T, Kodama H, Nishikawa SI.
Expression of alpha4-integrin defines the earliest precursor of hematopoietic cell lineage diverged from endothelial cells.
Blood.
1999;93:1168-1177
46.
Miraglia S, Godfrey W, Yin AH, et al.
A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning.
Blood.
1997;90:5013-5021
47.
Yin AH, Miraglia S, Zanjani ED, et al.
AC133, a novel marker for human hematopoietic stem and progenitor cells.
Blood.
1997;90:5002-5012
48.
Kriehuber E, Breiteneder-Geleff S, Groeger M, et al.
Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages.
J Exp Med.
2001;194:797-808 49. Makinen T, Veikkola T, Mustjoki S, et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J. 2001;20:4762-4773[CrossRef][Medline] [Order article via Infotrieve]. 50. Sleeman JP, Krishnan J, Kirkin V, Baumann P. Markers for the lymphatic endothelium: in search of the holy grail? Microsc Res Tech. 2001;55:61-69[CrossRef][Medline] [Order article via Infotrieve].
51.
Oliver G, Detmar M.
The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature.
Genes Dev.
2002;16:773-783
52.
Wilting J, Papoutsi M, Christ B, et al.
The transcription factor Prox1 is a marker for lymphatic endothelial cells in normal and diseased human tissues.
FASEB J.
2002;16:1271-1273
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  B. Gyan, B. Q. Goka, G. O. Adjei, J. K. A. Tetteh, K. A. Kusi, A. Aikins, D. Dodoo, M. L. Lesser, C. P. Sison, S. Das, et al. Cerebral Malaria Is Associated with Low Levels of Circulating Endothelial Progenitor Cells in African Children Am J Trop Med Hyg, April 1, 2009; 80(4): 541 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Bogos, F. Renyi-Vamos, J. Dobos, I. Kenessey, J. Tovari, J. Timar, J. Strausz, G. Ostoros, W. Klepetko, H. J. Ankersmit, et al. High VEGFR-3-positive Circulating Lymphatic/Vascular Endothelial Progenitor Cell Level Is Associated with Poor Prognosis in Human Small Cell Lung Cancer Clin. Cancer Res., March 1, 2009; 15(5): 1741 - 1746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sausville, A. A. Molinolo, X. Cheng, J. Frampton, N. Takebe, J. S. Gutkind, and R. A. Feldman RCAS/SCL-TVA Animal Model Allows Targeted Delivery of Polyoma Middle T Oncogene to Vascular Endothelial Progenitors In vivo and Results in Hemangioma Development Clin. Cancer Res., June 15, 2008; 14(12): 3948 - 3955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Reddy, Z. Zhou, K. Schadler, S.-F. Jia, and E. S. Kleinerman Bone Marrow Subsets Differentiate into Endothelial Cells and Pericytes Contributing to Ewing's Tumor Vessels Mol. Cancer Res., June 1, 2008; 6(6): 929 - 936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-S. Huang, J.-Y. Hsieh, Y.-H. Wu, C.-H. Jen, Y.-H. Tsuang, S.-H. Chiou, J. Partanen, H. Anderson, T. Jaatinen, Y.-H. Yu, et al. Functional Network Reconstruction Reveals Somatic Stemness Genetic Maps and Dedifferentiation-Like Transcriptome Reprogramming Induced by GATA2 Stem Cells, May 1, 2008; 26(5): 1186 - 1201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Bonaros, R. Rauf, E. Werner, B. Schlechta, E. Rohde, A. Kocher, J. Bonatti, and G. Laufer Neoangiogenesis after combined transplantation of skeletal myoblasts and angiopoietic progenitors leads to increased cell engraftment and lower apoptosis rates in ischemic heart failure Interactive CardioVascular and Thoracic Surgery, April 1, 2008; 7(2): 249 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Srinivasan, M. E. Dillard, O. V. Lagutin, F.-J. Lin, S. Tsai, M.-J. Tsai, I. M. Samokhvalov, and G. Oliver Lineage tracing demonstrates the venous origin of the mammalian lymphatic vasculature Genes & Dev., October 1, 2007; 21(19): 2422 - 2432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. C. Furtado, T. Marinkovic, A. P. Martin, A. Garin, B. Hoch, W. Hubner, B. K. Chen, E. Genden, M. Skobe, and S. A. Lira Lymphotoxin beta receptor signaling is required for inflammatory lymphangiogenesis in the thyroid PNAS, March 20, 2007; 104(12): 5026 - 5031. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. L. Aranguren, A. Luttun, C. Clavel, C. Moreno, G. Abizanda, M. A. Barajas, B. Pelacho, M. Uriz, M. Arana, A. Echavarri, et al. In vitro and in vivo arterial differentiation of human multipotent adult progenitor cells Blood, March 15, 2007; 109(6): 2634 - 2642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Gilner, W. G. Walton, K. Gush, and S. L. Kirby Antibodies to Stem Cell Marker Antigens Reduce Engraftment of Hematopoietic Stem Cells Stem Cells, February 1, 2007; 25(2): 279 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Bonaros, R. Rauf, D. Wolf, E. Margreiter, A. Tzankov, B. Schlechta, A. Kocher, H. Ott, T. Schachner, S. Hering, et al. Combined transplantation of skeletal myoblasts and angiopoietic progenitor cells reduces infarct size and apoptosis and improves cardiac function in chronic ischemic heart failure J. Thorac. Cardiovasc. Surg., December 1, 2006; 132(6): 1321 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. P. Fadini, S. V. de Kreutzenberg, A. Coracina, I. Baesso, C. Agostini, A. Tiengo, and A. Avogaro Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk Eur. Heart J., September 2, 2006; 27(18): 2247 - 2255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ikeda, R. K. Kundu, S. Ikeda, M. Kobara, H. Matsubara, and T. Quertermous Glia Maturation Factor-{gamma} Is Preferentially Expressed in Microvascular Endothelial and Inflammatory Cells and Modulates Actin Cytoskeleton Reorganization Circ. Res., August 18, 2006; 99(4): 424 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ma, Y. Ladilov, J. M. Moebius, L. Ong, C. Piechaczek, A. David, A. Kaminski, Y.-H. Choi, W. Li, D. Egger, et al. Intramyocardial delivery of human CD133+ cells in a SCID mouse cryoinjury model: Bone marrow vs. cord blood-derived cells Cardiovasc Res, July 1, 2006; 71(1): 158 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Fiedler, S. Christian, S. Koidl, D. Kerjaschki, M. S. Emmett, D. O. Bates, G. Christofori, and H. G. Augustin The Sialomucin CD34 Is a Marker of Lymphatic Endothelial Cells in Human Tumors Am. J. Pathol., March 1, 2006; 168(3): 1045 - 1053. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Arbab, V. Frenkel, S. D. Pandit, S. A. Anderson, G. T. Yocum, M. Bur, H. M. Khuu, E. J. Read, and J. A. Frank Magnetic Resonance Imaging and Confocal Microscopy Studies of Magnetically Labeled Endothelial Progenitor Cells Trafficking to Sites of Tumor Angiogenesis Stem Cells, March 1, 2006; 24(3): 671 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Rohde, C. Malischnik, D. Thaler, T. Maierhofer, W. Linkesch, G. Lanzer, C. Guelly, and D. Strunk Blood Monocytes Mimic Endothelial Progenitor Cells Stem Cells, February 1, 2006; 24(2): 357 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Glod, D. Kobiler, M. Noel, R. Koneru, S. Lehrer, D. Medina, D. Maric, and H. A. Fine Monocytes form a vascular barrier and participate in vessel repair after brain injury Blood, February 1, 2006; 107(3): 940 - 946. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Cherqui, S. M. Kurian, O. Schussler, J. A. Hewel, J. R. Yates III, and D. R. Salomon Isolation and Angiogenesis by Endothelial Progenitors in the Fetal Liver Stem Cells, January 1, 2006; 24(1): 44 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Religa, R. Cao, M. Bjorndahl, Z. Zhou, Z. Zhu, and Y. Cao Presence of bone marrow-derived circulating progenitor endothelial cells in the newly formed lymphatic vessels Blood, December 15, 2005; 106(13): 4184 - 4190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-G. Kopp, S. T. Avecilla, A. T. Hooper, S. V. Shmelkov, C. A. Ramos, F. Zhang, and S. Rafii Tie2 activation contributes to hemangiogenic regeneration after myelosuppression Blood, July 15, 2005; 106(2): 505 - 513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. P. Fadini, M. Miorin, M. Facco, S. Bonamico, I. Baesso, F. Grego, M. Menegolo, S. V. de Kreutzenberg, A. Tiengo, C. Agostini, et al. Circulating Endothelial Progenitor Cells Are Reduced in Peripheral Vascular Complications of Type 2 Diabetes Mellitus J. Am. Coll. Cardiol., May 3, 2005; 45(9): 1449 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Suzuki, T. Watabe, M. Kato, K. Miyazawa, and K. Miyazono Roles of vascular endothelial growth factor receptor 3 signaling in differentiation of mouse embryonic stem cell-derived vascular progenitor cells into endothelial cells Blood, March 15, 2005; 105(6): 2372 - 2379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Aoki and G. Tosato Lymphatic Regeneration: New Insights From VEGFR-3 Blockade J Natl Cancer Inst, January 5, 2005; 97(1): 2 - 3. [Full Text] [PDF]
|
|
|
|
|
|
R. A. Panepucci, J. L.C. Siufi, W. A. Silva Jr., R. Proto-Siquiera, L. Neder, M. Orellana, V. Rocha, D. T. Covas, and M. A. Zago Comparison of Gene Expression of Umbilical Cord Vein and Bone Marrow-Derived Mesenchymal Stem Cells Stem Cells, December 1, 2004; 22(7): 1263 - 1278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Aoki, M. Yasutake, and T. Murohara Derivation of Functional Endothelial Progenitor Cells from Human Umbilical Cord Blood Mononuclear Cells Isolated by a Novel Cell Filtration Device Stem Cells, November 1, 2004; 22(6): 994 - 1002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Hildbrand, V. Cirulli, R. C. Prinsen, K. A. Smith, B. E. Torbett, D. R. Salomon, and L. Crisa The role of angiopoietins in the development of endothelial cells from cord blood CD34+ progenitors Blood, October 1, 2004; 104(7): 2010 - 2019. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. He, I. Rajantie, M. Ilmonen, T. Makinen, M. J. Karkkainen, P. Haiko, P. Salven, and K. Alitalo Preexisting Lymphatic Endothelium but not Endothelial Progenitor Cells Are Essential for Tumor Lymphangiogenesis and Lymphatic Metastasis Cancer Res., June 1, 2004; 64(11): 3737 - 3740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J Makin, A. D Blann, N. A.Y Chung, S. H Silverman, and G. Y.H Lip Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells: Relationship with von Willebrand factor and tissue factor Eur. Heart J., March 1, 2004; 25(5): 371 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. B. Colvin Emphatically Lymphatic J. Am. Soc. Nephrol., March 1, 2004; 15(3): 827 - 829. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Herder, T. Tonn, R. Oostendorp, S. Becker, U. Keller, C. Peschel, M. Grez, and E. Seifried Sustained Expansion and Transgene Expression of Coagulation Factor VIII-Transduced Cord Blood-Derived Endothelial Progenitor Cells Arterioscler. Thromb. Vasc. Biol., December 1, 2003; 23(12): 2266 - 2272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Szmitko, P. W.M. Fedak, R. D. Weisel, D. J. Stewart, M. J.B. Kutryk, and S. Verma Endothelial Progenitor Cells: New Hope for a Broken Heart Circulation, June 24, 2003; 107(24): 3093 - 3100. [Full Text] [PDF]
|
|
|
|
|
|
H. Kubo and K. Alitalo The bloody fate of endothelial stem cells Genes & Dev., February 1, 2003; 17(3): 322 - 329. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
) in the
cultures was determined at 1, 3, 5, 7, and 14 days. (B) The number of
nonadherent VEGFR-3+ cells (
) in the cultures was
determined at 1 and 14 days by flow cytometry. The results are given as
means ± SEs of 3 independent experiments. During the 2-week
culture, a strong proliferation (more than 40-fold) of nonadherent
VEGFR-3+ cells can be seen.
